QSAR of 1,1'-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: A different approach for antiproliferative drug design

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 8, 2000, Pages 767-770

  Campos, Joaquín ^a   Núñez, María Del Carmen ^a   Rodríguez, Vicente ^a   Gallo, Miguel A ^a   Espinosa, Antonio ^a  

^a Facultad de Farmacia Campus de Cartuja s n   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE KINASE; DIBROMIDE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; CHEMICAL MODIFICATION; DRUG EFFECT; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION ANALYSIS; STRUCTURE ANALYSIS; YEAST;

CELL DIVISION; CHOLINE KINASE; DRUG DESIGN; HT29 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PYRIDINIUM COMPOUNDS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0342748370     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00080-9     Document Type: Article

References (24)

1. Kerr D.J., Workman P. New Molecular Targets for Cancer Chemotherapy. 1994;CRC Press, Boca Raton, FL.
2. Lacal J.C., Moscat J., Aaronson S.A. Nature. 330:1987;269.
3. Jiménez B., del Peso L., Montaner S., Esteve P., Lacal J.C. J. Cell. Biochem. 57:1995;141.
4. Ratnam S., Kent C. Arch. Biochem. Biophys. 323:1995;313.
5. Pelech S.L., Vance D.E. Biochem. Biophys. Acta. 779:1984;217.
6. Cuadrado A., Carnero A., Dolfi F., Jiménez B., Lacal J.C. Oncogene. 8:1993;2959.
7. 50 for ChoK inhibition ex vivo is 500 μM using purified ChoK from yeast.
8. Cannon J.G. Med. Res. Rev. 14:1994;505.
9. 50 against the human HT-29 cell line of 2.5 mM.
10. Hernández-Alcoceba R., Saniger L., Campos J., Núñez M.C., Khaless F., Gallo M.A., Espinosa A., Lacal J.C. Oncogene. 15:1997;2289.
11. Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C. Cancer Res. 1999, 3112.
12. Cram D.J., Steinberg H. J. Am. Chem. Soc. 73:1951;5691.
13. Vaidya R.A., Mathias L.J. J. Am. Chem. Soc. 108:1986;5514.
14. Jerchel D., Jakob L. Chem. Ber. 91:1958;1266.
15. 50) were calculated using a semilogarithmic plotting of the ratio PCho/(PCho+Cho) versus concentration of the inhibitors.
16. Typical procedure: HT-29 cells were grown in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% new-born calf serum (NCS) under standard conditions of temperature (37 °C), humidity (95 °C), and carbon dioxide (5%). The cells were seeded on 24-well plates and incubated for 24 h in DMEM supplemented with 10% NCS. Then the cells were washed with TD buffer (137 mM NaCl, 5 mM KCl, 20 mM Tris, pH 7.4) and incubated in DMEM containing the indicated amounts of serum and different concentrations of 5-FU derivatives. Three days later, the wells were aspirated, fresh medium added, and the cells maintained for three additional days. Quantification of the cells remaining in each well was carried out using the Crystal Violet method (See ref 17), with some modifications. Briefly, the cells were washed with TD buffer and fixed with 1% glutaraldehyde for 15 min. After having been washed again with TD, cell nuclei were stained with 0.1% Crystal Violet for at least 30 min, and washed three times with distilled water. Adsorbed dye was resuspended in 10% acetic acid and absorbance at 595 nm was determined in a spectrometer.
17. Gillies R.J., Didier N., Denton M. Anal. Biochem. 159:1986;109.
18. Munavalli S., Hsu F.-L., Szafraniec L.L., Beaudry W.T., Poziomek E. J. Magn. Reson. Chem. 24:1987;560.
19. Charton M. Prog. Phys. Org. Chem. 13:1981;119.
20. 3OD at 49.0).
21. Nelson G.L., Levy G.C., Cargioli J.D. J. Am. Chem. Soc. 94:1972;3089.
22. Rekker R.F., de Kort H.M. Eur. J. Med. Chem. 14:1979;479.
23. Högberg, T.; Norinder, U. In A Textbook of Drug Design and Development; Krogsgaard-Larsen, P.; Liljefors, T.; Madsen, U., Eds.; Harwood Academic Publishers: Amsterdam, 1996; pp 94-1360.
24. Dearden, J. C.; James, K. C. In Introduction to the Principles of Drug Design and Action; Smith, H. J., Ed.; Harwood Academic Publishers: Amsterdam, 1998; pp 167-207.